Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112554 · ClinicalTrials.gov registry record · Phase 3
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase 3 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
NCT00112554: Completed Phase 3 study, sponsored by Vion Pharmaceuticals.
NCT00112554 is a Phase 3 study that has completed, run by Vion Pharmaceuticals. The registered enrollment target is 420 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00112554, a Phase 3 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cytarabine and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This randomized phase III trial is studying cytarabine and VNP40101M to see how well they work compared to cytarabine alone in treating patients with relapsed acute myeloid leukemia.
Interventions
- OTHER placebo
- DRUG cytarabine
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00112554 record still lists
NCT00112554 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00112554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00112554 about?
NCT00112554 is a clinical study titled "Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as cytarabine and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This randomize...
What is the current status of trial NCT00112554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2005-03. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00112554?
The interventions under investigation include: placebo (OTHER), cytarabine (DRUG), laromustine (DRUG).
Who is sponsoring clinical trial NCT00112554?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00112554's enrollment target sits among peer trials
420 891st of 2000 higher than 1,102 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia